<DOC>
	<DOCNO>NCT02231723</DOCNO>
	<brief_summary>This open label , multi-center , multi-arm , dose-escalation study BBI608 administer combination Gemcitabine nab-Paclitaxel , mFOLFIRINOX , FOLFIRI , MM-398 5-FU leucovorin .</brief_summary>
	<brief_title>A Study BBI608 Combination With Standard Chemotherapies Adult Patients With Pancreatic Cancer</brief_title>
	<detailed_description>This open label , multi-center , multi-arm , dose-escalation study BBI608 administer combination either Gemcitabine nab-Paclitaxel , mFOLFIRINOX , FOLFIRI , MM-398 5-FU leucovorin . A study cycle consist daily continuous oral administration BBI608 four week ( 28 day ) combination Gemcitabine nab-Paclitaxel , mFOLFIRINOX , FOLFIRI , MM-398 5-FU leucovorin . Combination treatment continue 28 day cycle disease progression , unacceptable toxicity another discontinuation criterion meet . BBI608 may continue post-progression patient obtain potential clinical benefit , opinion investigator . If administration Gemcitabine and/or nab-Paclitaxel , mFOLFIRINOX , FOLFIRI , MM-398 5-FU leucovorin discontinue due chemotherapy backbone-related toxicity , administration BBI608 continue .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Signed write informed consent must obtain document accord International Conference Harmonisation ( ICH ) Good Clinical Practice ( GCP ) , local regulatory requirement , permission use private health information accordance Health Insurance Portability Accountability Act ( HIPAA ) prior studyspecific screening procedure . 2 . Patients must histologic cytologic evidence adenocarcinoma pancreas , core tissue biopsy surgical resection specimen . 3 . Patients must metastatic disease . Baseline image chest , abdomen pelvis ( CT MRI ) within 21 day prior initiation protocol therapy require . 1 . Patients must measurable disease define RECIST 1.1 . 2 . Patients locally advance unresectable pancreatic ductal adenocarcinoma exclude . 4 . Patients enrol onto Arm A ( Gemcitabine nabPaclitaxel ) Arm B ( mFOLFIRINOX ) allow two prior line systemic therapy , adjuvant therapy count one line therapy long disease recurrence occur &gt; 6 month last dose therapy . Prior systemic therapy metastatic setting allow long therapy contain BBI608 combination either Gemcitabine nabPaclitaxel mFOLFIRINOX . Toxicities related prior therapy must completely resolve ( except alopecia anemia ) , deem irreversible . 1 . Patients receive Gemcitabinebased therapy adjuvant set allow enrolled Arm A trial ( Gemcitabine nabPaclitaxel ) long last Gemcitabine administration least 6 month prior first dose BBI608 . 2 . Patients enrol onto Arm A ( Gemcitabine nabPaclitaxel ) allow prior mFOLFIRINOX combination BBI608 metastatic setting . 3 . Patients enrol onto Arm B ( mFOLFIRINOX ) allow prior Gemcitabine nabPaclitaxel combination BBI608 metastatic setting . 4 . Prior treatment radiotherapy allow . 5 . Patients enrol onto Arm C ( FOLFIRI ) Arm D ( MM398 5FU leucovorin ) must fail one prior line gemcitabinebased therapy without BBI608 metastatic setting . No additional line therapy metastatic setting allow . Prior adjuvant therapy gemcitabine allow long disease recurrence occur &gt; 6 month last dose therapy . Toxicities related prior therapy must completely resolve ( except alopecia anemia ) , deem irreversible . Prior treatment radiotherapy allow . 6 . ≥ 18 year age . 7 . Patients must ECOG Performance Status ≤ 1 . 8 . Male female patient childproducing potential agree use contraception avoidance pregnancy measure study 30 day last BBI608 dose . 9 . Females childbearing potential negative serum pregnancy test ( precede 72 hour first day BBI608 treatment ) . 10 . Patients biliary gastroduodenal obstruction must drainage surgical bypass prior start chemotherapy . 11 . Significant symptomatic amount ascites drain prior first dose BBI608 . 12 . Patients Warfarin/Dabigatran/Rivaroxaban anticoagulation may enrol long undergo weekly INR check first 2 month therapy . . Patients switch low molecular weight heparin may enrol weekly INR lab mandate patient . 13 . Aspartate transaminase ( AST ) level ≤ 2.5 x upper limit normal ( ULN ) alanine transaminase ( ALT ) ≤ 2.5 × upper limit normal ( ULN ) . For patient liver metastasis , AST ≤ 5 ULN , AST ≤ 5 ULN may enrol agree upon investigator medical monitor sponsor . 14 . Patients must total bilirubin level ≤ 1.5 x ULN ( ≤ 2 x ULN nonrising period 10 day prior initiation therapy ) . 15 . Creatinine level &lt; 1.0 x ULN creatinine clearance ≥ 60 mL/min/1.73 m^2 patient creatinine level institutional normal ( determined CockcroftGault equation ) . For patient Body Mass Index ( BMI ) &gt; 30 kg/m^2 , lean body weight use calculate GFR . 16 . Hemoglobin ( Hgb ) ≥ 9 g/dl 17 . Absolute neutrophil count ≥ 1.5 x 10^9/L 18 . Platelets ≥ 100 x 10^9/L 19 . Acceptable coagulation study demonstrate prothrombin time ( PT ) partial thromboplastin time ( PTT ) within normal limit ( +/15 % ) . 20 . Patient clinically significant abnormality urinalysis result . 21 . Life expectancy estimate ≥ 3 month . 1 . Anticancer chemotherapy , radiotherapy , immunotherapy , investigational agent within 14 day first dose BBI608 , except BBI608 washout period require . 1 . Patients may begin BBI608 date determine investigator medical monitor sponsor minimum 14 day since last receiving anticancer treatment include BBI608 , provide treatmentrelated adverse event resolve deem irreversible ( except alopecia ) . 2 . Patients previously receive BBI608 treatment PDAC BBI608118 ( BBI608201PANC ) study may continue BBI608 monotherapy discontinuation first chemotherapy backbone start second chemotherapy backbone . Patients may begin chemotherapy backbone date determine investigator medical monitor sponsor minimum 14 day maximum 30 day since last receiving anticancer treatment include BBI608 , provide treatmentrelated adverse event resolve deem irreversible ( except alopecia ) . 2 . Patients neuroendocrine neoplasms exclude . 3 . Major surgery , diagnostic surgery ( e.g. , surgery do obtain biopsy diagnosis without removal organ ) , within 4 week prior first dose . 4 . Any brain metastasis include leptomeningeal metastasis , exclude , even treat stable . 5 . History posterior reversible encephalopathy syndrome . 6 . Neurosensory neuropathy ≥ grade 2 baseline . 7 . Pregnant breastfeeding . 8 . Significant gastrointestinal disorder ( ) would , opinion Principal Investigator , prevent absorption orally available agent ( e.g. , Crohn 's disease , ulcerative colitis , extensive gastric resection small intestinal resection ) . 9 . Unable unwilling swallow BBI608 capsule daily . 10 . Uncontrolled chronic diarrhea ≥ grade 2 baseline . 11 . Uncontrolled intercurrent illness include , limit uncontrolled active infection ( include bacterial , viral fungal require systemic therapy ) , clinically significant nonhealing heal wound , symptomatic congestive heart failure , unstable angina pectoris , uncontrolled cardiac arrhythmia , significant pulmonary disease ( shortness breath rest mild exertion ) , uncontrolled infection psychiatric illness/social situation would limit compliance study requirement . 12 . Interstitial pneumonia extensive symptomatic interstitial fibrosis lung . 13 . History active malignancy . 14 . Enrollment additional investigational agent study . Enrollment concurrent observational study allow follow consultation Sponsor . 15 . Patients plan take vacation 7 consecutive day course study . 16 . For patient enrol onto Arm A ( Gemcitabine nabPaclitaxel ) . Known hypersensitivity Gemcitabine taxanes . . Patients history Gemcitabine toxicity adjuvant set require 1 dose level reduction exclude . b . Significant cardiac disease , include follow : unstable angina , New York Heart Association class IIIIV congestive heart failure , myocardial infarction within six month prior study enrollment . c. History hemolyticuremic syndrome . d. History posterior reversible encephalopathy syndrome . e. Known infection Human Immunodeficiency Virus ( HIV ) , and/or active infection hepatitis B , hepatitis C. f. History active Peripheral Artery Disease ( treated peripheral artery disease stable least 6 month allow ) . 17 . For patient enrol onto Arm B ( mFOLFIRINOX ) Arm C ( FOLFIRI ) 1 . Known hypersensitivity 5fluorouracil/leucovorin 2 . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency 3 . Known hypersensitivity oxaliplatin platinum contain compound 4 . Known hypersensitivity irinotecan 5 . Uncontrolled seizure disorder , active neurological disease , know CNS disease . 6 . Known Gilbert 's syndrome 7 . Significant cardiac disease , include follow : unstable angina , New York Heart Association class IIIV congestive heart failure , myocardial infarction within six month prior study enrollment . 18 . For patient enrol onto Arm D ( MM398 5FU leucovorin ) 1 . Prior irinotecan treatment 2 . Arterial thromboembolic event ( myocardial infarction , unstable angina pectoris , stroke ) &lt; 6 month prior enrollment 3 . Known hypersensitivity component MM398 , liposomal product , fluoropyrimidines leucovorin 4 . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Digestive System Neoplasms</keyword>
	<keyword>Endocrine Gland Neoplasms</keyword>
	<keyword>Pancreatic neoplasm</keyword>
	<keyword>Pancreatic cancer , adult</keyword>
	<keyword>Pancreatic cancer</keyword>
	<keyword>Pancreas cancer</keyword>
	<keyword>Pancreatic disease</keyword>
	<keyword>Adenoma , Islet Cell</keyword>
	<keyword>Carcinoma , Islet Cell</keyword>
	<keyword>Carcinoma , Pancreatic Ductal</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemzar</keyword>
	<keyword>Nab-paclitaxel</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Abraxane</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Fluorouracil</keyword>
	<keyword>5-FU</keyword>
	<keyword>MM-398</keyword>
</DOC>